asthma
ASTHMA
Asthma is a chronic inflammatory disease of the airways in the lungs of children and adults.
The patient usually complains of shortness of breath, chest tightness and coughing with wheezing.
Goals of treatment are effective symptom control with minimal or no exacerbations, minimal or no nocturnal and daytime symptoms, no limitations on activities, minimal or no need for reliever treatment, and minimal adverse effects of medication.

Definition

  • Defined as a heterogeneous disease characterized by chronic airway inflammation that results in recurrent episodes of wheeze, shortness of breath (SOB), chest tightness &/or cough that vary over time & in intensity, with variable expiratory airflow limitation

Signs and Symptoms

  • Symptoms are usually associated with airflow obstruction; which is often reversible either spontaneously or with treatment
  • These symptoms tend to be intermittent, variable, worse at night or upon waking, & provoked by triggers, eg exercise, allergens, weather changes, viral infections

Risk Factors

  • Asthma phenotypes (clusters of asthma characteristics) differ in clinical manifestations, pathophysiology & demographic location of the patient
    • Allergic asthma: present in childhood, with a positive family history of asthma, & previous history of allergy such as eczema, food allergy, allergic rhinitis, etc
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Radha Chitale, 2 years ago
Traffic and smog pollutants can alter airborne allergens to make them more potent, new research shows.
7 months ago
New drug applications approved by US FDA as of 16 - 31 October 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
6 months ago
New drug applications approved by US FDA as of 1 - 15 December 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Naomi Rodrig, 2 years ago
The BRAF inhibitors vemurafenib and dabrafenib, currently approved for use in advanced melanoma, are also effective in a subset of lung adenocarcinoma patients with BRAF mutations, according to a retrospective European trial presented at the European Lung Cancer Conference (ELCC) held in Geneva, Switzerland.